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A predominant feature of intestinal inflammation is the accumulation of neutrophils, which
dictates a fine balance between epithelial repair or progression to chronic inflammation.
While the processes of mucosal healing are well studied, how neutrophils advance an
inflammatory insult towards epithelial neoplasia is less understood. In this issue of the JCI,
Butin-Israeli et al. outline a mechanism whereby neutrophils control epithelial fitness and
genomic instability via delivery of miR-23a–and miR-155–containing microparticles.
Localized delivery of antisense oligonucleotides targeting miR-23a and miR-155 reversed
this genomic instability and accelerated mucosal healing. This mechanism of neutrophil-
derived microRNA shuttling opens up new therapeutic potential to enhance epithelial
healing and limit mucosal injury.
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Neutrophils control inflammation 
and mucosal healing
As the first immune cell recruited to sites 
of inflammation, neutrophils and their 
cargo are crucial for shaping mucosal 
responses to infection, injury, and repair. 
These cells play an essential role in clear-
ing invasive microorganisms and, when 
not tightly regulated, can trigger feed-for-
ward amplification loops that promote tis-
sue damage and chronic disease (1). Neu-
trophils utilize soluble mediators, such as 
cytokines, and processes, including pro-
duction and release of neutrophil extracel-
lular traps (NETs), reactive oxygen species 
(ROS), elastases, myeloperoxidase (MPO), 
and matrix metalloproteinases (MMPs), to 
perform antimicrobial functions and per-
petuate chronic inflammation. The impor-
tance of maintaining this fine balance is 
underscored in experimental mouse stud-
ies, which show that neutrophil depletion 
or inability to mount respiratory burst 
results in increased growth of commen-
sal bacteria or catastrophic experimental 
colitis, respectively (2–4). In patients with 
ulcerative colitis (UC), however, neutro-
phil accumulation in the stool positively 
correlates with active disease, and neu-
trophil infiltration into colonic tissue asso-
ciates with disease severity (5). Indeed, 
transepithelial migration of neutrophils 
into the lumen (crypt abscess) is a cardi-
nal pathological hallmark of UC; there-
fore, fine-tuning neutrophil transepithelial 
migration has been proposed to facilitate 
the management of UC (6), while sparing 
antimicrobial immunity.
Linking neutrophilic 
inflammation to epithelial 
genomic instability
There is a long-standing clinical link 
between chronic UC and increased risk 
of developing colorectal cancer (CRC), 
with recent meta-analysis showing CRC 
incidence of approximately 5% over 20 
years in patients with chronic UC (7, 8). 
A large Danish study with meta-analy-
sis of a population-based cohort found 
much lower cumulative CRC risks for 
UC patients over a 30-year period (9), 
though subgroups of patients, including 
those with early onset diagnosis, longer 
disease duration, or secondary complica-
tions such as primary sclerosing cholangi-
tis (PSC), were at increased risk of CRC. 
As such, understanding how episodes of 
active inflammation in the colonic muco-
sa impact epithelial health and genomic 
integrity remains critically important. A 
consensus understanding has been that 
chronic episodes of localized neutrophil-
ic inflammation is a contributing factor, 
resulting in oxidative stress–induced 
DNA damage, oncogene activation, and 
tumor progression (10, 11). However, an 
exact mechanistic understanding of the 
processes driving CRC in UC patients 
remains to be determined.
In this issue, Butin-Israeli and col-
leagues advance this knowledge gap by 
identifying a potentially novel and unex-
pected mechanism, whereby transmigrat-
ing neutrophils promote the accumula-
tion of double-strand DNA breaks (DSBs) 
in intestinal epithelial cells by shuttling 
microRNA-containing microparticles (12). 
Patients with active inflammatory bowel 
disease (IBD) exhibited a marked accumu-
lation of DSBs in intestinal epithelial cells, 
with a concomitant decrease in nuclear 
integrity. Moreover, these alterations were 
accompanied by increased expression of 
MPO, elastase, and inflammatory cyto-
kines, such as TNF, IL-6, and IFN-γ. Using 
a series of reductionist in vitro culture sys-
tems, including human colonic enteroids 
and in vivo models of biopsy-induced ster-
ile injury, Butin-Israeli et al. demonstrate 
that neutrophil-derived microparticles can 
selectively induce downstream effects on 
DNA damage. Neutrophil-derived micro-
particles alone induced DNA damage 
response in proliferating epithelial cells, a 
response that was blocked following inhi-
bition of microparticle uptake. A decrease 
in epithelial cell proliferation did not 
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A predominant feature of intestinal inflammation is the accumulation 
of neutrophils, which dictates a fine balance between epithelial repair 
or progression to chronic inflammation. While the processes of mucosal 
healing are well studied, how neutrophils advance an inflammatory insult 
towards epithelial neoplasia is less understood. In this issue of the JCI, 
Butin-Israeli et al. outline a mechanism whereby neutrophils control 
epithelial fitness and genomic instability via delivery of miR-23a–and 
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patients with active IBD and correlate 
with increased neutrophils, defective epi-
thelial micronuclei, increased epithelial 
DNA damage, and decreased lamin B1. 
One of the greatest practical challenges in 
developing a proof-of-concept therapeu-
tic modality to target these microRNAs 
is selective targeting to epithelial cells in 
the intestine. The authors overcame this 
hurdle by utilizing an elegant model of 
inflammation-independent wounding 
(needle biopsy with mouse colonoscopy) 
and delivered ASOs targeting miR-23a and 
miR-155 by site-directed microinjection 24 
hours after injury (12). This approach sub-
stantially protected the wound site from 
DSBs and markedly increased expression 
of lamin B1 and RAD51, and enhanced 
epithelial restitution and the rate of wound 
closure (Figure 1). It is worth noting that 
MicroRNAs are small noncoding RNAs 
(~22 nucleotides) that regulate an array of 
cellular processes by inhibiting the transla-
tion of protein-coding mRNA transcripts. 
Functional microRNAs encapsulated with-
in microparticles and microvesicles have 
been shown to shuttle into target cells in 
mucosal tissues during injury, inflamma-
tion, and infection (13–15); however, selec-
tively targeting specific microRNAs in vivo 
to a defined cell type is technically very 
challenging (Figure 1).
Targeting candidate microRNA 
for mucosal healing:  
no small task
In addition to in vitro systems and murine 
models, Butin-Israeli et al. demonstrated 
that expression of both miR-23a and miR-
155 is increased in mucosal biopsies from 
appear to be accompanied by induction of 
senescence or apoptosis, but it was asso-
ciated with shortened newly synthesized 
DNA fibers, suggesting that neutrophil-de-
rived microparticles regulated the integri-
ty of DNA elongation. The authors further 
identified two microRNAs (miR-23a and 
miR-155) that are shuttled within these 
microparticles and directly inhibit produc-
tion of RAD51, a critical DNA-repair pro-
tein, and nuclear envelope protein lamin 
B1. RAD51 catalyzes DNA strand exchange 
between homologous DNA partners, and 
is therefore essential for repairing DNA 
breaks by guiding repair templates. Impor-
tantly, pretreatment of epithelial cells 
with antisense oligonucleotides (ASOs) 
against miR-23a and miR-155 prevented 
neutrophil microparticle-associated DNA 
damage, demonstrating a selective effect. 
Figure 1. Therapeutic blockade of neutrophil-derived microRNAs limits epithelial DNA double-strand breaks and enhances intestinal mucosal healing. 
Neutrophil recruitment is a cardinal sign of intestinal inflammation, such as is seen with ulcerative colitis or mucosal wounding, and is associated with 
increased cytokine production, MPO, and ROS production. (A) At the injury site, neutrophils deliver microparticles containing miR-123a and miR-155 
to intestinal epithelial cells. These microRNAs promote degradation of the mRNAs encoding the nuclear envelop protein lamin B1 and the DNA mis-
match repair protein RAD51, leading to an increase in epithelial genomic instability, delayed wound healing, and possible neoplastic transformation. (B) 
Microinjection of antisense oligonucleotides (ASOs) targeting miR-123a and miR-155 prevent these miRNAs from binding their targets, thereby restoring 
expression of RAD51 and lamin B1 mRNA, improving genomic stability and promoting wound repair.
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are relatively understudied, extensions 
of Butin-Israeli et al.’s work may identify 
drug-responsive therapeutic candidates 
for both IBD and CRC.
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of macrophage via microvesicle-derived 
miR-17 and miR-221 (13). The mechanis-
tic understanding of these discrepant yet 
selective biological processes is sure to 
have major implications for our under-
standing of a multitude of inflammatory 
conditions.
The work of Butin-Israeli and col-
leagues also raises the question of wheth-
er all neutrophils (and neutrophil-derived 
microparticles) are created equally? That 
is to say, will multiple rounds of neutro-
phil hematopoiesis and consistent muco-
sal ulceration during active UC flares alter 
the fitness and function of microparticles? 
The stratification of neutrophils based on 
phenotype and function as pro- versus 
anticancer has been observed, and CRC 
can be stratified based on the composition 
of neutrophil and myeloid-derived sup-
pressor cell (MDSC) infiltrates (19, 20). 
These phenotypic data are lacking, but 
warranted, for the continuum of chronic 
mucosal disease in UC; however, immune 
cell phenotypes are sure to be confounded 
by continuing responses to the commensal 
microbiota and UC-associated dysbiosis.
Mucosal healing and remission are 
emerging as the primary therapeutic goals 
for preventing CRC in UC patients (21, 22). 
The work by Butin-Israeli et al. raises the 
question of how treatment responses of 
UC patients to an armamentarium of cur-
rent therapeutics might alter the identified 
neutrophil/microparticle/epithelial cell 
axis? Recent analysis has suggested that 
current therapies, such as 5-aminosalicylic 
acid (5-ASA) and thiopurine, have chemo-
preventive effects in UC (23, 24), but there 
is limited evidence on the effects of bio-
logic therapy on the incidence of CRC for 
UC patients. To date, it is not known how 
these biotherapeutics impact microparti-
cle and microRNA biology. As eluded to by 
Butin-Israeli and colleagues, the utility of 
future microRNA therapeutics will always 
be hampered by the technical challenges 
of cell-specific targeting and subverting 
the issue of multiple off-target mRNA 
candidates for each miRNA. However, by 
utilizing selective microRNAs as a prism 
to separate and underscore major disease 
pathways in vivo, elegant bodies of work 
such as the one by Butin-Israeli and col-
leagues can uncover master circuits driv-
ing disease in both IBD and CRC. While 
both microRNA and microparticle biology 
off-target effects of microRNA blockade 
could have profound long-term conse-
quences for epithelial function. For exam-
ple, miR-155 is known to repress hypox-
ia-inducible factor HIF-1α, which has a 
protective role in maintaining intestinal 
epithelial barrier integrity (16–18). Thus, 
blocking miR-23a and miR-155 with ASOs 
may impact other reparative gene expres-
sion profiles. In addition, it is not known 
how this approach works in the context 
of inflammation and microbiome dysbi-
osis, such as occurs during active flares 
in UC patients, and it may yield different 
results. However, it should be noted that 
antibody-mediated depletion of neutro-
phils had similar effects as ASO-mediated 
blockade of miR-23a and miR-155. Acute 
depletion of neutrophils in a dextran sul-
phate sodium–induced model of colitis 
reduced DSBs and reversed the imbalance 
of lamin B1 and RAD51. Thus, Butin-Israe-
li and colleagues have identified a remark-
ably powerful miR-23a/miR-155/lamin 
B1/RAD51 axis as a reparative pathway 
that warrants further investigation.
Microparticle-derived microRNAs: 
the how, why, and what’s next
The linear focus of the Butin-Israeli et al. 
study on neutrophil-derived micropar-
ticles makes clinical sense, considering 
that accumulation of transepithelial neu-
trophils within colonic crypts is the pre-
dominant pathological hallmark of active 
UC (2). However, during UC, there is a 
multitude of innate leukocytes, includ-
ing monocytes, macrophages, and eosin-
ophils, present that are also capable of 
secreting microparticles and expressing 
distinct microRNAs. An intriguing ques-
tion raised by this work is why are specif-
ic microRNAs selectively packaged into 
microparticles by discrete stimuli (i.e., 
only expressed in activated neutrophils)? 
This question is further emphasized in the 
work of Butin-Israeli and colleagues, as 
another RAD51-targeting miRNA, miR-
103, which is also increased in activated 
neutrophils, was not incorporated into 
neutrophil-derived microparticles. In con-
trast, recently published data demonstrate 
that neutrophil-derived microparticles 
containing miR-223 regulate lung epithe-
lial cells in the setting of both sterile and 
infectious insults (14), whereas the injured 
lung epithelium regulates the recruitment 
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